Skuldtech has focused its research and development on genomic biomarkers and their use in combination with advanced therapeutics to improve diagnostics and treatments.

Thus, Skuldtech is involved in different research programs, including three projects granted by the European Commission (FP6):

• SYSCO: Systematic functional analysis of intracellular parasitism as a model of genomes conflict - Example of Leishmania (http://www.syscoproject.eu/);

• CONCO: Applied venomics of the cone snail species Conus consors for an accelerated, cheaper, safer and more ethical production of innovative biomedical drugs (http://www.conco.eu);

• USDEP: Capture and enrichment of emerging pathogens for multiple and ultra-sensitive diagnostics (this project focuses on the development of detection tools against several viruses threatening human health including dengue, respiratory virus, Hantavirus, etc.).

In the clinical setting, Skuldtech has identified new biomarkers associated with leukemia in order to tailor a treatment to a patient's unique polymorphism and therefore increase chances of recovery or remission. These biomarkers are currently being tested in the hospital of Nîmes (France).

In the study of drug effects, Skuldtech is collaborating with Pr. Michel Audran (Montpellier University, France) to identify and validate biomarkers involved in EPO drug abuse. The project also involves the Science and Industry Against Blood doping (SIAB) research consortium and has been granted by several anti-doping agencies: United State Anti-Doping Agency (USADA), World Anti-Doping Agency (WADA) and French Anti-Doping Agency (AFLD). About 40 biomarkers have already been identified. They are currently being tested in clinical settings.

Skuldtech's pathological and biological research actions, expertise and know-how have been described in several scientific publications: Genomics, Nucleic Acid Research, Oncogene, etc. To obtain more information, please contact the company.